EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nanoparticle‐encapsulated neuropeptide Y provides robust seizure protection in SCN1A ‐derived epilepsy

Samantha L Reed, Lauren M Aiani, Eesha Faiz, Emmanuel Adediran, Morris Benveniste, Kevin S Murnane, Martin D'Souza, Andrew Escayg iD, Jennifer C Wong

Epilepsia · 2026

DOI: 10.1111/epi.18649 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Samantha L Reed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Neuropeptide Y, NAV1.1 Voltage-Gated Sodium Channel, Nanoparticles, Seizures. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Neuropeptides have garnered great interest as potential treatments for epilepsy due to their impact on neuronal excitability through modulation of ion channels and neurotransmitter receptor activity. Neuropeptide Y (NPY) is a 36‐amino acid neuropeptide that is expressed primarily by γ‐aminobutyric acidergic (GABAergic) interneurons. NPY has widespread effects on the brain, at both the cellular (e.g., reducing excitatory glutamatergic transmission) and circuit levels (e.g., increasing food intake, improving learning and memory, increasing seizure resistance). Previous studies have demonstrated antiseizure effects of NPY following invasive brain delivery methods or gene therapy approaches to increase the expression of NPY or its receptor activity. However, these routes of administration pose challenges for translation into clinical practice.

Methods

To overcome these obstacles, we generated a nanoparticle formulation to encapsulate neuropeptides. In the current study, we evaluated the ability of nanoparticle‐encapsulated NPY (NP‐NPY) to increase resistance to 6 Hz‐, pentylenetetrazole‐, and hyperthermia‐induced seizures in mouse models of SCN1A ‐derived epilepsy. We also examined the ability of NP‐NPY treatment to protect against spontaneous seizures in Scn1a +/− mutant mice, a model of Dravet syndrome. Quantitative reverse transcription polymerase chain reaction was performed to compare expression levels of NPY and its receptors in hippocampi from Scn1a +/− mutants and wild‐type littermates.

Results

We found that intranasal NP‐NPY administration was able to provide robust protection against induced seizures in two mouse models of SCN1A‐ derived epilepsy and reduce spontaneous seizure frequency in Scn1a +/− mutant mice. Significance These results provide support for further evaluation of NP‐NPY as a treatment for SCN1A‐ derived epilepsy and possibly other epilepsy subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuropeptide YNAV1.1 Voltage-Gated Sodium ChannelNanoparticlesSeizuresEpilepsyAnticonvulsantsAnimalsMiceMice, TransgenicDisease Models, AnimalMaleMice, Inbred C57BLPentylenetetrazole

Stichwörter der Autor:innen

SCN1ADravet syndromeepilepsynanoparticleneuropeptide Y

Substanzen

Neuropeptide YNAV1.1 Voltage-Gated Sodium ChannelScn1a protein, mouseAnticonvulsantsPentylenetetrazole

Autor:innen und Institutionen

  • Department of Human Genetics, Emory University, Atlanta, Georgia, USA.
  • Department of Pharmaceutical Sciences, Center for Drug Delivery, Nanotechnology Lab, Mercer University, Atlanta, Georgia, USA.
  • Neuroscience Institute, Morehouse School of Medicine, Atlanta, Georgia, USA.
  • Department of Pharmacology, Toxicology, & Neuroscience, Louisiana State University Health Shreveport, Shreveport, Louisiana, USA.
  • Louisiana Addiction Research Center, Louisiana State University Health Shreveport, Shreveport, Louisiana, USA.
  • Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport, Shreveport, Louisiana, USA.

ORCID-Profile: Andrew Escayg

Förderung

  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Reed, S. L., Aiani, L. M., Faiz, E., Adediran, E., Benveniste, M., Murnane, K. S., D'Souza, M., Escayg, A., & Wong, J. C. (2026). Nanoparticle‐encapsulated neuropeptide Y provides robust seizure protection in SCN1A ‐derived epilepsy. Epilepsia. https://doi.org/10.1111/epi.18649

Vancouver

Reed SL, Aiani LM, Faiz E, Adediran E, Benveniste M, Murnane KS, et al. Nanoparticle‐encapsulated neuropeptide Y provides robust seizure protection in SCN1A ‐derived epilepsy. Epilepsia. 2026. doi:10.1111/epi.18649

BibTeX
@article{Reed2026,
  author = {Reed, Samantha L and Aiani, Lauren M and Faiz, Eesha and Adediran, Emmanuel and Benveniste, Morris and Murnane, Kevin S and D'Souza, Martin and Escayg, Andrew and Wong, Jennifer C},
  title = {Nanoparticle‐encapsulated neuropeptide Y provides robust seizure protection in SCN1A ‐derived epilepsy},
  journal = {Epilepsia},
  year = {2026},
  doi = {10.1111/epi.18649}
}
Kostenlos starten →